University at Buffalo
Teams will seek to develop treatment options that could benefit patients with multiple sclerosis, hemophilia and more
BUFFALO, N.Y. Two University at Buffalo drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
Message :
Required fields
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs
The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting
The approval adds to Biogen’s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-term treatment of patients with MS
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI® (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). The new route of administration offers comparable efficacy and safety to the TYSABRI intravenous (IV) formulation building on the therapy’s long-term
(0)
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs
The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting
The approval adds to Biogen s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outcomes as part of the long-term treatment of patients with MS
CAMBRIDGE, Mass., April 07, 2021(Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). The new route of administration offers comparable efficacy and safety to the TYSABRI intravenous (IV) formulation building on the therapy s long-term data, established clinical benefits and well-characterized saf
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Share:
Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactions
PLEGRIDY has a well-characterized safety and efficacy profile with a proven ability to reduce relapses and delay disability progression
Treatment access and options have become increasingly important for MS patients in the COVID-19 environment
CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY